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Abstract
Multiple studies have established that hyperinflammatory response induced by SARS CoV-2 is a main
cause of complications and death in infected subjects. Such dysfunctional immune response has been
described as a dysregulated and exacerbated production of cytokines and chemokines that attracts and
activates inflammatory cells, which start and sustain pulmonary and systemic damage, thus causing
complications that lead to multi organ failure and death. Therefore, we suggest that blocking key
inflammation receptors could help to reduce migration and activation of T cells,
monocytes/macrophages and neutrophils, thus mitigating the cytokine dysregulation and averting severe
complications and death. Importantly, the optimum treatment for COVID-19 severe patients should
combine a modulator of the immune response plus a direct antiviral drug against SARS-CoV-2, in order to
address both the hyperinflammatory effects of the immune dysregulation and the viral load. Methods:
Maraviroc (MVC), a CCR5 antagonist, and Favipiravir (FPV), an antiviral, will be evaluated single and
combined, added to the treatment currently used at the Hospital General de México Dr. Eduardo Liceaga
for severe COVID-19 patients. One hundred patients will be allocated in four arms [Current treatment only
(CT), CT+MVC, CT+FPV, CT+MVC+FPV]. Percentage of patients free of mechanical ventilation or death at
day 28, immunophenotyping and viral load will be compared between groups. Discussion: New immune
focused therapies are targeting strong inflammation mediators such as IL-6 and IL1-β; nevertheless, to
our best knowledge, only one study explores chemotaxis control. The use of a drug therapy that
addresses both the regulation of the immune response and the inhibition of viral replication could at the
same time, help to alleviate the hyperinflammatory condition and reduce the time of the viral clearance
process, therefore improving treatment outcomes.

Introduction
The COVID-19 (Coronavirus Disease 2019) pandemic caused by infection of SARS-CoV-2 (Severe Acute
Respiratory Syndrome Coronavirus 2) has caused a global mortality surrounding 3% (1). Multiple studies
have found that the hyperinflammatory response induced by SARS-CoV-2 is one of the main causes of
severity and death. In severe COVID-19 patients, an association was found between pneumonitis and/or
ARDS (Acute Respiratory Distress Syndrome), high serum levels of proinflammatory cytokines, extensive
lung damage and microthrombosis (2). The late stage of the disease is difficult to manage and many
patients die (3,4). Based on the reports of the Chinese Disease Control Center, Cascella and
cols. (5) classified the patients according to clinical severity in three groups (Table 1).

It has been proposed that the critical course of the disease is caused by an exacerbated and poorly
understood immune response, linked to the phenomenon known as “cytokine storm” or cytokine release
syndrome (6). Albeit it is not completely clear what initiates and propagates the cytokine storm, the
severity of COVID-19, combined with rapid pandemic spread, has placed unprecedented pressure on the
global healthcare system, and therapeutic strategies are urgently needed.
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Pathological studies of patients lethally infected by COVID-19 had reported acute pulmonary edema,
abundant infiltration of inflammatory cells, multiple organ failure, thromboembolic complications and
septicemia (7,8). One of the mechanisms that could precede functional and tissue damage is the
infiltration of inflammatory cells, triggered by the release of chemokines (9,10).

Gene studies in lung samples identified overexpression of CCL2 and CCL3 chemokines (11). Furthermore,
Huang and cols. (12) reported that besides leukopenia and lymphopenia, hospitalized patients had higher
plasma concentrations of CCL3 and CCL4 upon admission than healthy subjects. They also mention that
SARS and MERS physiopathology is outlined by an increase of proinflammatory cytokines and
chemokines in serum (IL-Iβ, IL-6, IL-12, IFN-γ and CCL2). Previously, serum CXCL10 and CCL7 were
identified as predictors of progression (13). Hence, it is of notice that the cytokine storm is accompanied
by chemokine-induced migration of white cells, particularly CCL2, CCL3, CCL7 and CXCL10.

CCR5 is a G-protein-coupled chemokine receptor expressed by dendritic cells, monocytes, macrophages,
natural killer (NK) cells, Th1 cells, Th17 cells and Treg cells which has multiple ligands, namely CCL3,
CCL4, CCL5, CCL7 and CCL8 (14).

In respiratory diseases, it has been shown that CCR5 is involved in neutrophil recruitment to the
lungs (15). In that sense, in human subjects with chronic pulmonary inflammatory diseases, infiltrated
neutrophils overexpress CCR5, induced by activation of TLRs and NOD2 (16). Neutrophils’ infiltration in
pulmonary capillaries, alveolar extravasation and neutrophilic mucositis have already been observed in
COVID-19. (17). Despite the precise mechanism that drives such infiltration remains unknown, it is
feasible that CCR5 may play a critical role in the immunopathology of COVID-19 (18).

Along with phagocytosis and oxidative burst, neutrophils have another resource to eliminate pathogens:
NETosis, a distinct form of programmed, necrotic cell death characterized by the neutrophilic release of
network organized protein and DNA structures known as “neutrophil extracellular traps” (NETs), which are
able to capture and entangle such pathogens (19). Though beneficial against pathogens, NETs could
stimulate certain disease processes (20). Excessive formation of NETs could trigger a chain of
inflammatory reactions that destroys surrounding tissue and facilitates micro thrombosis (21). Previous
reports associate aberrant formation of NETs to pulmonary disorders, namely ARDS (22). The increase in
D dimer described as a severity marker in COVID-19 severe patients, could be related to NETosis, since it
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has an essential role in the start and progression of thrombosis in veins and arteries (23). Hence, all these
neutrophil functions could be part of both the tissue damage and microthrombosis in COVID-19.

As previously mentioned, the chemokines increased in COVID-19 severe patients are CCL3, CCL5 and
CCL7. All these are CCR5 ligands; thus, our group hypothesizes that a CCR5 blockade could prevent
leukocyte migration to the lung and attenuate the cytokine storm, and can be considered a therapeutic
target (24). Moreover, a monoclonal antibody targeted against CCR5 (Leronlimab, also known as
PRO140) was able to restore lymphocyte levels and decrease IL-6 in 10 COVID-19 patients (18).

One of these drugs is Maraviroc (MVC) (25), an oral CCR5 antagonist, mainly used as an anti-retro viral
that impedes binding of the gp120 protein to CCR5, thus avoiding viral internalization. (26). MVC has not
been widely studied in the context of reduction of hyperinflammatory conditions. However, some reports
have found interesting effects in modulation or resolving of general inflammatory conditions, such as
reduction of cytokine expression by in vitro human adipocytes (27), and as an alleviating agent of
hemorrhage-induced hepatic injury in rats by a PPAR-γ depending pathway (28). Furthermore, it was used
in a phase II study to minimize the graft vs. host disease in bone marrow stem cell transplant in pediatric
patients (29). It has also been observed that MVC decreases mucosal inflammation (30), VCAM-1 (31), T
cell infiltration, neuroinflammation (32) and endothelial dysfunction (33). Regarding the lung, a model of
induced hemorrhagic shock in rats reported that MVC has a protective role against pulmonary
damage (34). All the aforementioned, along with the broad safety range of MVC, good tolerance an low
incidence of adverse effects (35) makes it an excellent candidate to be used as a modulator of the
dysregulated immune response in COVID-19.

On the other hand, in silico studies (36,37), aimed to find possible candidates for the treatment of SARSCoV-2, and found that MVC could have a direct antiviral activity by binding to the main protease of the
virus (Mpro). Other in silico studies propose that MVC could have an antiviral effect based on structural
similarity to inhibitors of viral proteins (38), and on its binding capacity to the hinge site receptor binding
motif (RBM), and fusion peptide (FP) (39). Moreover, there is also a report of MVC inhibiting SARS-CoV2
multiplication in cell culture (40). Altogether, this body of evidence suggests that MVC could not only
block the CCR5-dependent migration to the lung, but also reduce the viral load.

We hypothesized that an effective treatment for COVID-19 severe patients should combine a modulator
of the immune response with a direct antiviral drug against SARS-CoV-2, in order to address both the
hyperinflammatory effects of the immune dysregulation and the viral load, thus yielding best results.
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Favipiravir (FPV), directly inhibits viral replication and transcription by selective inhibition of the viral
enzyme RNA-dependent RNA polymerase (RdRP) (41–44).

FPV has been used successfully against A H1N1 influenza (45,46). Regarding COVID-19, an open
randomized study in 80 mild patients found that FPV reduced the time of viral clearance by 50%
compared to Lopinavir/Ritonavir with less adverse effects (47). Another open randomized study in
moderate patients reported FPV to be more effective in clinical recovery compared to Arbidol (48). An in
vitro study found that FPV is capable to suppress the SARS-CoV-2 infection at high concentrations (49). A
clinical study combining FPV with methylprednisolone for severe COVID-19 pneumonia reported good
results (50). Finally, to date there are more than 30 studies registered in the U.S. National Library of
Medicine (ClinicalTrails.gov) that evaluate FPV and 4 studies (including this) with MVC in COVID-19
patients, which are the following:
a.

A multicenter study in two hospitals in Madrid and Barcelona, Spain (NCT04441385).

b.

A study in Rhode Island, USA (NCT04435522).

c.

A study in Seville, Spain, (NCT04710199).

To our best knowledge, at the moment (September 2021) there is not a study that evaluates both drugs
for COVID-19 in the same trial.

Design And Methods
This a proof-of-concept (51,52) open label, randomized, controlled, stratified by sex trial will be carried
out in hospitalized patients at the Hospital General de México “Dr. Eduardo Liceaga” (HGMEL), located at
Mexico City, Mexico. The protocol has been duly registered and approved by the Institutional Committees
of Research, Ethics and Biosafety (Approval number DI/20/407/04/38), and registered in the Federal
Commission for Prevention of Sanitary Risks, COFEPRIS (Approval number 203300410A0290/2021)

Design

Four arms will be conducted: (Figure 1)

1. Current therapy (CT) only: The current treatment for hospitalized COVID-19 patients at the HGMEL,
consisting in enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per
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currently used at HGMEL.
2. CT+MVC: [CT] + [300 mg. MVC p.o. bid for 10 days]
3. CT+FPV: [CT] + [FPV p.o. for a 7-day period: 1600 mg bid on day 1 and 600 mg bid days 2-7]
4. CT+MVC+FPV: [CT] + [600 mg. MVC bid for 10 days] + [200 mg. FPV for a 7-day period. 1600 mg bid
on day 1 and 600 mg bid days 2-7]

FIGURE 1

Eligibility criteria

Screening: Upon admission, screening criteria will be applied in the Emergency service to select the
candidates
Adult patients (18-80)
Within 12 days of the appearance of symptoms
Severe non-critical clinical stage at admission
At least one of the following risk factors: DM, BMI≥28, hypertension history or age >65

Inclusion criteria
These will confirm the selected subjects for enrollment.
Positive for SARS-CoV-2 confirmed by PCR or rapid antigen test
PaFi 150-300 (or SpFi equivalent)
LDH (Lactate dehydrogenase) >250
Thoracic image with >25% pulmonary compromise infiltration, according to RALE score (2-4 points).
Normal hepatic function, defined as a maximum of a fivefold increase of transaminases.
Signed informed consent.
Women in fertile capability must accept the use of a contraceptive method for 90 days after
treatment completion.

Exclusion criteria
Page 7/21

Pregnant or lactating women
Participating in another clinical trial
Clinical evidence of an infectious disease different from COVID-19 at the time of admission
Oxygen saturation <70% (Unassisted)
Glomerular filtration rate <30ml/min/1.73m2 and known history of pre-existing chronic kidney
disease (Chronic kidney disease stage 4 or 5)
Coronary disease (acute or chronic)
Previous history of allergies to MVC or FPV
Autoimmune disorders
History of any previous transplant
Patients with polyconsumption of toxic substances (Defined as a combination of two or more
addictions to tobacco, alcohol, marihuana, cocaine, etc)
Treatment with erythromycin
Under treatment with psychotropic drugs of any kind.
Cancer of any kind
On mechanically assisted ventilation at the time of randomization

Elimination criteria
Withdrawal of the informed consent
Patients who fail to receive two consecutive doses of the trial drugs.

Endpoints

Primary: Progression-free survival rate (PFS) for mechanical ventilation or death [time frame: day 28]

Secondary:
Progression-free survival rate for mechanical ventilation or death [Time frame: day 5]
Time of improvement in at least 2 categories in the WHO 7-category ordinal scale (53) [Time
frame: day 15]
Evaluation of the response to treatment of the hyperinflammatory condition by analysis of the
change rate in percentage of lymphocytes, monocytes, and neutrophils, as well as
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proinflammatory chemokine and cytokine levels [Time frame: day 10-1]

Sample size

The calculation was performed to compare survival curves using EPIDAT 4.2, based upon the 2020
casuistry observed at the Infectology Department of the HGMEL, with a mechanical ventilation FPS rate
in severe cases of 65%, and an expected value of 80%, with a confidence level of 80%. For a 4-arm study,
the following is obtained:

Sample size and power for survival curves comparison:

Groups:

4
Estimated losses:
Confidence level:

15%
80.0%

Expected FPS (%)
Group 1: 65
Group 2: 75
Group 3: 75
Group 4: 80

Power (%)
--------------80.0

Total

--------------98
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Therefore, 25 patients will be allocated by group: 100 total.

Randomization

Subjects will be randomized using EPIDAT v. 4.2 considering stratification by sex.

Statistical analysis

For the calculation of the efficacy, all those patients that completed the study with no major deviations
from the foreseen results (improvement, progression to critical or death) will be considered as the
Population per Protocol (PP). In order to avoid bias by the effect of termination of treatment due to
causes different from the foreseen ones, the modified intention to treat (mITT) will be calculated, based
on the criterion of at least one dose taken and at least one measurement after basal of the endpoints.

The primary endpoint (PFS for mechanical ventilation or death) [time frame: day 28] will be analyzed
using a Kaplan-Meier Log Rank model to compare the 4 arms.

The secondary endpoints will be compared between arms as follows:

PFS rate for mechanical ventilation or death [Time frame: day 5]: Kaplan-Meier Log Rank model.
Time of improvement in at least 2 categories in the WHO 7-category ordinal scale (53) (This variable
is applicable to responders only) [Time frame: day 15]: Kruskal-Wallis test.
Change rate in expression of cytokines and chemokines in serum [Time frame: day 10-1]: One-way
ANOVA will be used to compare change rate of each cytokine/chemokine. Additionally, a Principal
Component Analysis (PCA) will be performed for clusters identification and their relationship with
treatment response.
Change rate in the patterns of activation, trafficking and exhaustion in peripheral blood lymphocytes,
monocytes and neutrophils [Time frame: day 10-1]: Data will be analyzed for subpopulations,
frequencies (%) and mean fluorescence intensities (MFI) for each molecule and their interactions.
By subsets: Gating using Flowing Software
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By clusters: PCA using RStudio

Data will be controlled by confounding factors (BMI, sex, hypertension, and diabetes).

IBM SPSS version 21 and RStudio v. 3.6.3 will be used for the statistical analysis. A confidence interval of
95% and a significance level of p ≤ 0.05 will be considered.

Procedure

Patients eligible by screening criteria are invited to participate in the protocol. Upon acceptance, a detailed
explanation is given, and signature of a written informed consent form is requested. One copy of the
signed informed consent is kept in the patient’s file, and one more is given to the patient.

If the confirmatory tests for inclusion criteria show that not all are met, or any exclusion criterion is found,
the subject is informed and is not recruited.

Once participation is confirmed, patients are registered in the data collection sheet and undergo a general
clinical and medical record assessment. Samples for blood count, blood chemistry and blood gases are
collected, as well as saliva for viral load and blood for evaluation of immune status. A general approach
to the study is presented in Table 2

NPE will be used to measure SARS-CoV-2. Blood samples will consist of 25ml: for cytokines and
chemokines measurement on serum and activation and trafficking markers on leukocytes. Saliva,
plasma, and leukocytes samples will be transported to the BSL3 laboratory of CIENI-INER (Research
Center for Infectious Diseases at the National Respiratory Diseases Institute) for these analysis.

Participation of the subjects will end upon discharge by improvement or death. If patients progress to
critical condition, tablets will be crushed and administered using a nasogastric tube.
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Even in the occurrence of anticipated discharge or death, the patient’s information is kept and processed
for data analysis, as long as the patient or their relatives do not retire their consent. Likewise, participation
of the subjects is terminated before term if a complication or adverse effect occurs that can be related to
the drug under study and is ruled so by the responsible physician. If that is the case, the necessary
medical support is given to correct the adverse effect, and the patient is kept in observation.

Reporting of AE/SAE is done by trial physicians on a daily basis in compliance with the current procedure
of the Hospital, which demands reporting to the Pharmacovigilance, Ethics, and Biosafety Committees of
the Hospital within the first 24 hours. In turn, the Pharmacovigilance Committee informs the Uppsala
Monitoring Centre.

Follow up

Discharged patients are contacted by telephone on a weekly basis until day 28. Questions are addressed
for symptoms and possible adverse effects.

The study will be considered finished when all the enrolled subjects calculated in the sample size
complete their participation.

Discussion
In this study, we propose the use of MVC and/or FPV as a therapeutic resource to prevent or ameliorate
the immune dysregulation, decrease the viral load and reduce complications and death in severe patients
in risk of progressing to critical. The cells accountable for such dysregulation express receptors like CCR5,
which mediate their trafficking to the lungs. Therefore, it is considered a therapeutic target.

In recent studies with other CCR5 inhibitors such as Leronlimab, a significant decrease in peripheral blood
levels of CCL5, IL-6 and IL-1β, as well as inflammation and viral load has been observed. This could be
related with a reduction of inflammation markers like ferritin, D-dimer and CRP (54,55). Therefore, MVC
could, as mentioned before, prevent the trafficking of pro-inflammatory leukocytes to the lungs through
CCR5 blockade in a similar manner. Nevertheless, MVC has a technical advantage, because unlike
Leronlimab, it is an orally administered tablet that does not require special conditions for transport,
handling and administration.
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MVC is a CCR5 antagonist that could also have an antiviral effect, albeit it has not been evaluated in the
context of COVID-19. Alongside, the results could be potentiated by the direct effect of an antiviral such
as FPV. It has been reported that FPV decreases the viral load by day 4-7 (47), which leads us to think that
an early intervention would bring better results for the arms where FPV is going to be evaluated .
Moreover, it has been observed that there exists a relationship between viral load and severity (56).

Despite newly developed SARS-CoV-2 vaccines are being massively applied, current evidence suggests
that COVID-19 is a disease that will coexist with mankind for a very long period of time. Moreover,
pharmacologic strategies used for treatment have not proven completely effective.

Thence, more studies of different therapeutic targets are needed to search for resources that help to
improve the patients’ prognosis. The use of a drug therapy that addresses both the regulation of the
immune response and the inhibition of viral replication could at the same time, help to alleviate the
hyperinflammatory condition and reduce the time of the viral clearance process. This study is intended to
compare the therapy currently used at Hospital General de Mexico “Dr. Eduardo Liceaga” to treat COVID19 on severe non-critical patients, which does not comprise either an inflammation modulator or an
antiviral, to a strategic therapy focused on the aforementioned mechanisms of pathogenicity.

Limitations

1) Viral strains were not considered. 2) MVC is an expensive drug. 3) Albeit the sample size calculation
was focused on reliable parameters and therefore is solid, the sample size is limited for a better
understanding of the interaction of other variables such as clinical improvement and days of hospital
stay. Hence, a greater number of subjects is desirable for further studies. 4) Open studies can be
potentially affected by the effect of multiple biases (e.g. placebo effect)

Trial Status
At the time of submission of this paper (September 2021), 9 patients had been recruited. The Institutional
Committees of Research, Ethics and Biosafety of the HGMEL approved the protocol on June 24, 2020
(registration number DI/20/407/04/38). Registered in NIH’s Clinical Trials (https://clinicaltrials.gov) on
July 17 2020, COMVIVIR NCT 04475991. Recruitment is estimated to be completed by February 2022
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Feature

Mild
Disease
Severe
Disease

Critical
Disease

%
Cases
81

Mild or absent pneumonia
Dyspnea,
Respiratory rate ≥ 30/min,
Oxygen saturation (SpO2) ≤ 93%,
Kirby index (ratio between partial oxygen pressure, PaO2 and oxygen
fraction inspired, FiO2) < 300,
Pulmonary infiltrate in thorax imaging > 50%.
Respiratory failure
Septic shock
Multiple organ failure.

14

5

Table 2. Overview of the study, including time frames, eligibility, allocation of subjects and sampling
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STUDY PERIOD
Enrollment

Allocation

Post-allocation

Screening

Treatment period

period
EVENT

-D2

D1

D2

D3

D4

D5

D6

D7

D8

D9

D10

X

X

X

X

X

X

X

X

X

X

Arm B: MVC + CT

X

X

X

X

X

X

X

X

X

X

Arm C: FVP + CT

X

X

X

X

X

X

X

X

X

X

Arm D: MVC + FVP

X

X

X

X

X

X

X

X

X

X

Informed consent

X

Screening criteria

X

Inclusion criteria

X

D0

Follow-up

Close

period

out

D15

D28

D180

X

Allocation
INTERVENTION
Arm A: Current
Therapy (CT)

+ CT
ASSESSMENTS
Variables
Hematic biometry

X

Electrocardiogram

X

Viral Load

X

Chemokines

X

X

Cytokines

X

X

Chest x-ray

X
X

X

X

X

X

X

Disease progress

X

Days free of

X

mechanical
ventilation

Figures
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X
X
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Figure 1
Overall design of the study and description of the arms, main events and sampling days. CT: Currently
used treatment. MVC: Maraviroc. FPV: Favipiravir. NPE: Nasopharyngeal exudate
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